The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.
SBC: TRANSGENOMIC, INC. Topic: 103
DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: STRYKAGEN CORPORATION Topic: NIAMS
DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: PSI (Phytochemical Services, Incorporated) Topic: 213
DESCRIPTION provided by applicant Clinical trials testing the potential health benefits of immune enhancing dietary supplements have produced inconsistent results A major problem contributing to these inconsistent outcomes is that these studies have used a wide variety of poorly characterized products Attempts to solve this product quality control problem using chemical standardization method ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health